By Colin Kellaher

Merck & Co. on Tuesday said the U.S. Food and Drug Administration granted priority review to V114, the drug maker's investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults.

Merck's V114 targets 15 serotypes, including two not targeted by the currently available 13-valent pneumococcal conjugate vaccine.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The Kenilworth, N.J., said the agency set a target action date of July 18 for the application.

Merck, which is also developing V114 for use in children, said the European Medicines Agency is also reviewing an application for licensure of the vaccine in adults.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 12, 2021 07:23 ET (12:23 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Merck (NYSE:MRK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Merck
Grafico Azioni Merck (NYSE:MRK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Merck